Vomiting in Medical Technology

New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal

... for experiencing these side effects. Nausea and vomiting are uncomfortable and bothersome and can have an ... and significant reduction in nausea and/or vomiting compared to oxycodone IR. Results from the ... to oxycodone IR, the incidence of nausea and/or vomiting was significantly lower with tapentadol IR 50-mg: ...

Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer

... (46% vs 63%), stomatitis (41% vs 15%), vomiting (33% vs 44%), diarrhea (21% vs 35%), ... nausea (48% vs 40%), diarrhea (46% vs 39%), vomiting (32% vs 22%), constipation (31% vs 31%), ... asthenia (7%), fever (8%), alopecia (9%), vomiting (8%), diarrhea (5%), and stomatitis (5%) ...

Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma

... (including anorexia) (each 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), headache, ... pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and ... neuralgia (36% vs 1%), leukopenia (33% vs 30%), vomiting (33% vs 16%), pyrexia (29% vs 19%), fatigue (29% ...

Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients

... (including anorexia) (each 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), ... pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea ... neuralgia (36% vs 1%), leukopenia (33% vs 30%), vomiting (33% vs 16%), pyrexia (29% vs 19%), fatigue (29% ...

CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors

... 69%, 55%; fatigue 54%, 61%; nausea 36%, 49%; vomiting 20%, 29%; anorexia 19%, 27%; headache 19%, 23%; ... respectively, were fatigue 7%, 9% nausea; 1%, 1%; vomiting <1%, 2%; anorexia 1%, 1%; headache 2%, 4%; ... and overall, respectively were: nausea 10%, 53%; vomiting 6%, 42%; headache 6%, 41%; fatigue 4%, 34%; ...

Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients

... (including anorexia) (each 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), ... (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and ... neuralgia (36% vs 1%), leukopenia (33% vs 30%), vomiting (33% vs 16%), pyrexia (29% vs 19%), fatigue (29% ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... nausea (50%-73%), muscle cramps (28%-62%), vomiting (23%-58%), diarrhea (43%-57%), musculoskeletal ... (31%), constipation (21%), diarrhea (22%) and vomiting (21%). The most common (>10%) Grade 3/4 ... hydration for patients experiencing diarrhea or vomiting is recommended. Gastrointestinal symptoms, ...

Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease

... nausea (50%-73%), muscle cramps (28%-62%), vomiting (23%-58%), diarrhea (43%-57%), musculoskeletal ... peripheral edema was not reported. Nausea and vomiting were the most commonly reported individual ... (40%; 37%), rash and related terms (38%; 53%), vomiting (38%; 35%), musculoskeletal pain (37%; 30%) ...

New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients

... neuralgia (36% vs 1%), leukopenia (33% vs 30%), vomiting (33% vs 16%), pyrexia (29% vs 19%), fatigue (29% ... (including anorexia) (each 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), headache, ... pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and ...

GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)

... chemotherapy-induced nausea and vomiting (CINV). Adding a single oral dose regimen of ... for about five days and the risk of nausea and vomiting without prophylaxis is greater than 90 ... To achieve complete response, patients had no vomiting or retching and took no rescue medications for ...

Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting

... p.m. Abstract No: 9617 induced Nausea and vomiting Location: S Hall ... nausea and vomiting (CINV) associated with ... nausea and vomiting (CINV) GLIADEL(R) Wafer Treatment of ...

GlaxoSmithKline Reports Further Progress of Oncology Portfolio

... pm, S-Hall A1 Chemotherapy-Induced Nausea and vomiting (CINV) Phase III results of a novel ... regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately ... regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly ...

BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)

... significant reductions in renal toxicity, vomiting and anemia further support our belief in this ... significant reduction in chemotherapy-induced vomiting for patients receiving Tavocept in comparison to ... such as kidney damage and chemotherapy-induced vomiting were also less in Tavocept treated ...

MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study

... the prevention of Chemotherapy-Induced Nausea and vomiting (CINV), prevention of nausea and vomiting associated with radiotherapy, and prevention of Post-Operative Nausea and vomiting (PONV). MonoSol Rx's thin film technology ...

Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes

... (17%); thrombosis/embolism (6%); nausea (12%); vomiting (11%); dyspnea (11%); and chest pain (9%). The ... (80%); thrombosis/embolism (7%); nausea (84%); vomiting (58%); constipation (44%); anorexia (35%); ... (62%); nausea (39%); constipation (30%); vomiting (25%); diarrhea (21%); stomatitis/pharyngitis ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... superficial edema (60%-74%), nausea (50%-73%), muscle cramps (28%-62%), vomiting (23%-58%), diarrhea (43%-57%), musculoskeletal pain (38%-49%), and rash ... (48%; 53%), abdominal pain (40%; 37%), rash and related terms (38%; 53%), vomiting (38%; 35%), musculoskeletal pain (37%; 30%), and hemorrhage (26%; 34%).(+) ...

Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia

... fatigue (28%), headache (31%), constipation (21%), diarrhea (22%), and vomiting (21%). The most common ( > 10%) Grade 3/4 adverse reactions were ... superficial edema (60%-74%), nausea (50%-73%), muscle cramps (28%-62%), vomiting (23%-58%), diarrhea (43%-57%), musculoskeletal pain (38%-49%), and rash ...

Mission Pharmacal Launches CitraNatal(R) Assure Prescription Prenatal Vitamin

... and nervous system(5) and may help some women reduce severe nausea or vomiting during pregnancy(6). It also helps the body maintain blood glucose levels, ... (6) Sahakian V., et al. Vitamin B6 Is Effective Therapy for Nausea and vomiting of Pregnancy: A Randomized, Double Blind Placebo-Controlled Study. ...

Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults

... headache (5 percent), abdominal pain (4 percent), nausea (3 percent), vomiting (2 percent), and rash (2 percent). In treatment-experienced adult ... nausea (7 percent), abdominal pain (5 percent), rash (6 percent), vomiting (4 percent), asthenia (3 percent), headache (2 percent), abdominal ...

F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy

... only patch to provide up to five consecutive days of control of nausea and vomiting for patients receiving a moderately and/or highly nausea-inducing chemotherapy regimen. Chemotherapy-induced nausea and vomiting (CINV) are commonly cited by patients undergoing chemotherapy as highly ...

QRxPharma Releases Additional Phase 3 Data for Q8003IR 'Dual Opioid' Pain Therapy

... on the preferred dose of Q8003IR. Typical of opioid drugs, nausea and vomiting were the most common adverse events. Of patients receiving the 12mg/8mg ... no incidences of severe nausea were reported. 32% of patients reported vomiting with initial dosing (18% mild to moderate and 14% severe). 20% of patients ...

Help! I'm Sick. How Do I Handle My Diabetes?

... grams of carbohydrates every hour or so. -- Stay hydrated - If you are vomiting or have diarrhea, or have a fever, try to drink a cup of fluid each hour ... or if there are ketones in your urine for more than 12 hours; if you are vomiting or have diarrhea for more than six hours; if you have a fever that keeps ...

Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting

... asthenia (22% vs 18%), nausea (48% vs 40%), diarrhea (46% vs 39%), vomiting (32% vs 22%), constipation (31% vs 31%), mucositis/stomatitis (20% vs ... appetite decrease, including reports of anorexia (36%), pyrexia (34%), vomiting (33%) and anemia (29%). Twenty percent of patients reported at least one ...

Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia

... (cethromycin 2.4%, Biaxin 3.1%), nausea (cethromycin 4.5%, Biaxin 1.4%), vomiting (cethromycin 1.4%, Biaxin 1.0%), abdominal pain (cethromycin 1.4%, Biaxin ... (13/288) (4/291) (7/260) (10/257) (20/548) (14/548) vomiting 1.4% 1.0% 2.7% 1.6% 2.0% 1.3% ...

Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine

... receiving the PF regimen had greater grade 3/4 nausea (6.7% vs. 0.6%), vomiting (4.5% vs. 0.6%) and stomatitis (11.2% vs. 4.6%). Commonly seen adverse ... (11% vs. 4%), stomatitis (27% vs. 21%), lethargy (10% vs. 5%) and vomiting (10% vs. 8%). The incidence of other grade 3/4 events was similar between ...

ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study

... asthenia (56%/49%), nausea (49%/37%), constipation (35%/30%) and vomiting (29%/23%). The most common adverse events seen in patients with carcinomas ... (73%/48%), diarrhea (72%/25%), nausea (55%/29%), abdominal pain (45%/26%), vomiting (41%/25%), fever (34%/27%), constipation (30%/26%), and headache ....

July 2009 Mayo Clinic Women's HealthSource Highlights Food Storage Safety, Energy Therapies and Vitamins and Minerals

... of food storage safety and how to avoid bad bacteria, such as E. coli and salmonella. Safe food storage matters. While diarrhea and vomiting caused by food poisoning usually resolve without treatment, about 325,000 people in the United States are hospitalized every year because of food ...

FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent

... and low blood pressure, especially if you take water pills, are on a low-salt diet, get dialysis treatments, have heart problems, or get sick with vomiting or diarrhea. Lie down if you feel faint or dizzy. Call your doctor right away. In clinical studies, the most common side effect experienced ...

Orkin Warns of Four Pests to Avoid this Fourth of July

... threatened, they repeatedly sting, causing blisters or pustules. Wasps , including yellow jackets and hornets, can sting, causing headaches, fever, vomiting and other symptoms. These insects can even be deadly to people allergic to their venom. According to the American Academy of Allergy, Asthma ...

New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients

... signs of hepatitis B infection, such as: feel very tired skin or eyes look yellow little or no appetite vomiting muscle aches dark urine clay-colored bowel movements fevers chills stomach discomfort skin ...

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

... signs of hepatitis B infection, such as: feel very tired skin or eyes look yellow little or no appetite vomiting muscle aches dark urine clay-colored bowel movements fevers chills stomach discomfort skin ...

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

... -- most frequently the gastrointestinal tract, liver and skin. Patients with mild-to-moderate GI GVHD typically develop symptoms of anorexia, nausea, vomiting and diarrhea. If left untreated, GI GVHD can progress to ulcerations in the lining of the GI tract, and in its most severe form, can be fatal. ...

Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight

... exenatide was 0.5%. Weight loss (0.9 to 1.8 kg) was observed across all doses. The most frequently reported adverse events included nausea, vomiting and headache. At the 30 mg weekly dose, fewer than 10% of patients experienced nausea and vomiting, which subsided after week eight. Albiglutide ...

Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry

... to 10% among lurasidone subjects) for lurasidone versus placebo were nausea (16% vs. 3%), headache (11.1% vs. 10%), constipation (11.1% vs. 5.6%), vomiting (11.1% vs. 5.6%), dyspepsia (11.1% vs. 3.3%), somnolence (11.1% vs. 3.3%), insomnia (10.0% vs. 3.3%) and sedation (10.0% vs. 4.4%). Lurasidone had a ...

Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients

... displayed dose proportionality and no accumulation between cycles. SF1126 was well tolerated. The most common side effects were grade 1 or 2 vomiting (42%), nausea (39%), diarrhea (33%), fever (22%), fatigue (19%), chills (14%), and puritis (11%). There were two patients with grade 3 toxicity, one ...

Complications and Costs for Obesity Surgery Declining

... failure and pneumonia fell by between 50 percent and 29 percent. Rates for other complications, such as ulcers, dumping (involuntary vomiting or defecation), hemorrhage, wound reopening, deep-vein thrombosis and pulmonary embolism, heart attacks and strokes remained relatively unchanged. ...

CareHere's Electronic Medication System Proves 100 Percent Effective in Response to Recall

... less, of the active drug than the appropriate dose. Patients taking the recalled medication were at risk for complications ranging from nausea and vomiting to cardiac arrhythmias and death. "While we often speak of the significant improvements in employee wellness and the measurable savings our ...

New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management

... with TRILIPIX to check for liver or kidney problems. Patients should contact their healthcare provider if they experience abdominal pain, nausea, or vomiting while taking TRILIPIX. These may be signs of inflammation of the gallbladder or pancreas. Women who are pregnant should not take statins and should ...

Vantia Therapeutics' Pipeline Continues to Mature

... 15,000 people world wide, is characterised by episodes of swelling in various parts of the body including the airways. It can lead to pain, nausea, vomiting and death by asphyxiation, and an oral treatment would be expected to provide advantages over existing therapies. Dr Jim Phillips, CEO of ...

Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer

... (10 percent or greater) adverse events included fatigue (50 percent), diarrhea (27 percent), nausea, anorexia, and neutropenia (all 23 percent), vomiting and dizziness (18 percent). The most common Grade 3/4 toxicity was neutropenia (23 percent) and was the only Grade 3/4 adverse event that occurred ...